Proven, Predictive, Published
Cardiovascular disease encompasses a wide range of clinical conditions that are a consequence of genetics, physiologic and metabolic conditions as well as adverse drug reactions. The availability of human cell models that could represent and be used to interrogate these various factors would have a profound impact on the effort to find new medicines and cures.
CDI scientists have used iPS cell technology to develop iCell® Cardiomyocytes. These human heart cells recapitulate apparently healthy human cardiac biology and overcome the limitations of existing heart cell models, offering these benefits:
- 95% pure population of ventricular, atrial, and nodal cells
- Clinically relevant cardiac disease phenotypes
- Relevant clinical targets for cardiovascular disease
- Highly reproducible across a wide range of applications
iCell Cardiomyocytes: More Publications, More Applications, Less Cost
With the most peer-reviewed publications and application notes/protocols, as well as the lowest cost per cell of any commercially available iPS cell-derived cardiomyocyte product, iCell Cardiomyocytes are the platform of choice. They enable a wide range of applications spanning disease research, drug discovery, toxicity testing, and regenerative medicine, including the following:
- Cardiac hypertrophy studies
Novel human in vitro model used to recapitulate clinical phenotypes, detect known and novel biomarkers, and identify new targets for drug discovery and therapy (Drawnel et. al, 2014; Arrarwal et al., 2014; Traister et al., 2014; Zhi et al., 2012).
- Arrhythmia testing
Highly predictive model used for detecting drug-induced arrhythmia – resulting in changing regulatory paradigms
- Cardiotoxicity assessment
Retrospective analyses leveraged to uncover previously undetected mechanisms of drug-induced cardiotoxicity and provide relevant data in support of Investigational New Drug (IND) applications (Talbert et al., 2014; Cameron et al., 2013; Doherty et al., 2013; Rana et al., 2012; Cohen et al., 2011).